問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Otolaryngology

Division of Radiation Therapy

Division of Hematology & Oncology

Taipei Medical University Hospital (在職)

Division of Infectious Disease

Division of Thoracic Medicine

Division of Hematology & Oncology

更新時間：2024-12-10

陳盛鈺Chen, Sheng-Yu
  • Principal Investigator
  • Clinical Trial Experience (year)

  • 211015@h.tmu.edu.tw

Recruiting Trial

37Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳盛鈺

List

58Cases

2020-08-31 - 2027-12-31

Phase III

Active
A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN)

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma(ESCC)

  • Test Drug

    Durvalumab

Participate Sites
11Sites

Recruiting11Sites

2024-06-01 - 2027-12-31

Phase I

Active
A Phase 1, First-in-Human, Open-label, Dose- escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141 in Subjects with Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    injection

Participate Sites
3Sites

Recruiting3Sites

2023-07-07 - 2026-07-31

Phase I

Active
A Global First-in-Human Study in NSCLC, HNSCC, and Solid Tumors with Azirkitug (ABBV-514) as a Single Agent and in Combination with Budigalimab or Bevacizumab

  • Condition/Disease

    NSCLC, HNSCC, and Advanced Solid Tumors

  • Test Drug

    N/A N/A

Participate Sites
5Sites

Recruiting5Sites

2022-09-01 - 2025-12-31

Phase I

Active
A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 as Monotherapy and in Combination With Bevacizumab in Adult Subjects With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    ABBV-400

Participate Sites
11Sites

Not yet recruiting3Sites

Recruiting8Sites

2020-05-12 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2017-08-10 - 2025-01-09

Phase III

Completed
A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma

  • Condition/Disease

    Patients with unresectable, previously untreated advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC).

  • Test Drug

    Injection Injection

Participate Sites
12Sites

Recruiting12Sites

2021-07-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2020-01-06 - 2026-01-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-06-01 - 2029-12-31

Phase II

Active
A Phase 2, Randomized, Open-label Three-arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009)

  • Condition/Disease

    Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

  • Test Drug

    Pembrolizumab (MK-3475)/ Lenvatinib (E7080/MK-7902)

Participate Sites
7Sites

Recruiting7Sites

2022-11-01 - 2037-11-01

Others

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB